GlassScriptPhysician profile
Roya Nassiri
NPI 1538749114
$3,916.34
in general payments reported to CMS, 2019-2025
24 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $526 · 2023: $1,350 · 2024: $1,546 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,390.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.84 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $427.15 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $397.93 | 2022-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.78 | 2022-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $339.89 | 2022-2025 | Stelara, Tremfya |
| Pfizer INC. | $304.67 | 2023-2024 | |
| Madrigal Pharmaceuticals | $198.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $198.10 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $155.77 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $148.42 | 2022-2024 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $108.29 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $90.67 | 2022-2024 | Givlaari |
| Fresenius Kabi USA, LLC | $83.06 | 2024 | Idacio |
| Regeneron Healthcare Solutions, INC. | $77.11 | 2022-2024 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $64.46 | 2024-2025 | Iqirvo, Bylvay |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $46.44 | 2024 | Voquezna |
| Organon LLC | $46.18 | 2024-2025 | Renflexis, Hadlima |
| Aimmune Therapeutics, INC. | $34.99 | 2024 | |
| Intercept Pharmaceuticals, INC. | $33.47 | 2024-2025 | |
| Lilly USA, LLC | $33.02 | 2024 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.20 | 2024 | Cyltezo |
| Celltrion USA INC. | $19.46 | 2024 | Zymfentra |
| Nestle Healthcare Nutrition INC. | $18.71 | 2023 | |
| Genzyme Corporation | $15.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roya Nassiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.